Quanterix, Eli Lilly to collaborate on Alzheimer's blood-based biomarker research

Quanterix Corp. has announced a collaboration with Eli Lilly and Co. to advance the diagnosis, monitoring and treatment of Alzheimer’s disease, according to a press release.

Via the collaboration, Quanterix will receive a nonexclusive, worldwide license to Lilly’s proprietary P-tau217 antibody technology, which may aid in near-term use in research-only products and services and future in vitro diagnostic applications. The collaborators also agreed on a framework for future projects centered around the development of Simoa immunoassays.

Under the agreement, Lilly will fund $11 million of development with the Quanterix Accelerator group in 2022. According to the release, the agreements aim to advance blood-based biomarkers into routine clinical use.

“Our collaboration leverages Lilly’s advanced antibody technology with the ultra-sensitive Simoa technology, which we believe has the potential to identify Alzheimer’s early in the pathology, potentially before the onset of severe symptoms — a concept we call ‘neurodiagnostic therapy,’” Kevin Hrusovsky, chairman and CEO of Quanterix, said in the release. “We believe this collaboration has the potential to advance the field of Alzheimer’s research, treatment and diagnostics.”